Drawing for TUTOPLAST

USPTO serial 88092176

TUTOPLAST

Reviewed by CopyMark Law Group

Reg. 6048481Status 702Registered
Filing date
Status date
Registration date
May 5, 2020
Examiner
KENEALY, NATALIE LANGFORD
Law office
Historical data usage

What this means

Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with TUTOPLAST?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Max Vern

Max Vern Amster, Rothstein & Ebenstein LLP405 Lexington AvenueNew York, NY 10174United States

Goods and services

ClassDescriptionStatusFirst use
005[ Connective tissue transplant and implant material in the nature of living tissues; ] biological allograft and xenograft tissue intended for subsequent implantation or transplantation; biological implants and transplants, namely, processed human or animal connective or supportive tissue for implantation or transplantation into humans; processed animal or human donor tissue for the replacement of soft tissue in orthopaedic surgery; surgical implants and transplants comprised of processed, tissue for the restoration, regeneration or reinforcement of human tissueACTIVENov 21, 2019
037Sterilization of human or animal tissue for use in implantation for scientific and medical purposesACTIVEAug 27, 2018
040Processing and preservation of human or animal tissue for use in implantation for scientific and medical purposesACTIVEAug 27, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 11, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 11, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 10, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 22, 2026E815TEAS SECTION 8 & 15 RECEIVED—
May 5, 2025REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 5, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 31, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 30, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 20, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Mar 20, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 3, 2020IUAFUSE AMENDMENT FILED—
Mar 3, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 17, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 23, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 23, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 3, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 18, 2019PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 17, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 17, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 17, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 15, 2019ALIEASSIGNED TO LIE—
Jun 11, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 14, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 14, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 14, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 10, 2018DOCKASSIGNED TO EXAMINER—
Sep 5, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 28, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance